Optimizing PARP Inhibitor Therapies in Veterans With Prostate Cancer

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/EFK865. NCPD/ILNA credit will be available until November 29, 2025.

Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.

Disclosure information is available at the beginning of the video presentation.

YouTube Tags:
Grace Cullen DNP FNP-BC AOCNP PMGT-BC FPCN, Kassandra August-Marcucio DNP APRN ACNP-BC SANE, prostate cancer, nurses, ZERO Prostate Cancer, mCRPC, metastatic castration-resistant prostate cancer, PARP inhibitors, genomic testing, biomarkers, veterans, VA healthcare, BRCA, BRCA1/2, HRR, ARSI, anemia, hematologic AEs, nausea, fatigue, hypertension, cardiovascular AEs, PROfound, TRITON2, TRITON3, PROpel, MAGNITUDE, TALAPRO-2, olaparib, rucaparib, abiraterone, enzalutamide, niraparib, talazoparib